• 肿瘤基因检测
  • 药企合作
  • 燃石早检
  • 新闻动态

    新闻中心 学术成果

  • 患者专区
  • 关于燃石

    公司简介 合作伙伴 核心资质 管理团队 技术平台 加入我们 联系我们

  • Genomic Testing
  • Biopharma Partner Services
  • Early Detection
  • News & Activities

    News Publications

  • Patient Zone
  • About Us

    Overview Partners Qualifications Management Team Technologies Join Us Contact Us

  • INVESTORS

    • Creative Techniques Sequencing Platform

    • 1.UMI technique

      UMI reduces noise disturbance in sequencing to hit higher sensitivity and specificity. To effectively test low-frequency mutation, it pioneers in preceding NGS testing in early cancer screening (for IB-IIA stage patients for example, Burning Rock’s UMI technique can raise positive rate in the blood test from <50% to>70%).

    • 2.Techniques for MSI determination by NGS

      Legend：TMB is presented in Burning Rock Dx’s OncoScreen plus® report and MSI is presented in Burning Rock Dx’s OncoScreen plus® report and ColonCore ® report. A package of techniques for MSI determination by NGS is independently developed. Helping patients test all types of variation, such techniques cover all target therapies and immunotherapies.

    • 3.HS library preparation technique

      · The technique's efficient linking system and high-efficiency and high-fidelity amplification system assures high transfer efficiency · Tailored for FFPE samples and ctDNA in particular, this technique is less demanding on sample quality and quantity

    • 4.Indexing-specific paired-end technique

      Addressing the indexing contamination problem that prevails in many links outright, the technique enhances data fractionation accuracy in high-sensitivity blood ultra-deep sequencing.

    • 5.Automatic library preparation technique

      Burning Rock is the first to put into practice automatic library preparation in cancer-targeted NGS area, leading to less manual operation error and higher library preparation efficiency.

    • 6.Technical validation

      Burning Rock's creative techniques have been validated by ddPCR.